Skip to main content

Table 4 Pre-specified study clinical endpoints

From: Continuous versus intermittent short-acting β2-agonists nebulization as first-line therapy in hospitalized children with severe asthma exacerbation: a propensity score matching analysis

Clinical endpointsContinuous nebulization
(n = 56)
Intermittent nebulization
(n = 56)
Treatment effect (continuous vs. intermittent nebulization)
n%n%Clinical parametersUnadjusted analysisAdjusted analysisa
Effect95%CIP-valueEffect95%CIP-value
Success4987.53257.1Risk difference (%)30.414.6, 46.1< 0.00139.522.7, 56.3< 0.001
     SHR2.031.30, 3.170.0022.701.72, 4.22< 0.001
Failure712.52442.9Risk difference (%)−30.4−46.1, −14.6< 0.001−39.5−56.3, −22.7< 0.001
     SHR0.250.11, 0.580.0010.120.05, 0.31< 0.001
LOS (hour), mean ± SD52.8±28.259.1±66.4RMST difference (mean)−2.92−14.54, 8.700.623−9.88−24.18, 4.420.176
  1. Abbreviation: LOS Length of stay; RMST Restricted mean survival time; SHR Sub-distributional hazard ratio (under competing risk time-to-event analysis).amultivariable analysis adjusted for potential confounders (prognostic factors, treatment at emergency room, and co-medications during admission)